Chest
Clinical InvestigationsSLEEP AND BREATHINGClinical Outcomes Related to Interface Type in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome Who Are Using Continuous Positive Airway Pressure
Section snippets
Subjects
Eligible patients were between 18 years and 70 years of age, had an OSAHS diagnosis (apnea-hypopnea index [AHI] ≥ 15/h or AHI ≥ 5 plus daytime sleepiness),11 and had not received CPAP treatment previously. Exclusion criteria included wake resting arterial oxygen saturation < 90%, evidence of upper airway tract infection or flu-like symptoms at the time of titration, elective surgery scheduled before conclusion of the study, or prior surgical intervention for OSAHS. Patients were not eligible if
Patient Characteristics
Forty-two patients were enrolled in the study. Three patients were unable to complete the protocol. One patient traveled to Europe and was unable to use the equipment. An unrelated medical condition developed in one patient; he was dropped from the study but maintained on CPAP treatment. One patient was unavailable for follow-up.
Thirty-nine patients completed the 6-week protocol. Twenty-four patients underwent full-night CPAP titrations, and 15 patients underwent split-night studies. Twenty
Discussion
This is the first report of CPAP use, adverse effects, and residual sleep-disordered breathing with nasal pillows, when compared to nasal mask. Fewer overall adverse effects, including less air leak and better self-reported sleep quality, were reported when CPAP was used with nasal pillows. Attempted CPAP use during the first 3 weeks of therapy favored nasal pillows, but use per night did not differ between the two types of interface. The greater attempt at CPAP use with nasal pillows was
References (30)
- et al.
Patient compliance with nasal CPAP therapy for sleep apnea
Chest
(1986) - et al.
Side effects of nasal continuous positive airway pressure in sleep apnea syndrome
Chest
(1995) - et al.
Self-reported use of CPAP, and benefits of CPAP therapy
Chest
(1996) - et al.
What characterizes patients who are unable to tolerate continuous positive airway pressure (CPAP) treatment?
Respir Med
(2000) - et al.
Heated humidification or face mask to prevent upper airway dryness during continuous positive airway pressure therapy
Chest
(2000) - et al.
Self-reported vs measured compliance with nasal CPAP for obstructive sleep apnea
Chest
(1993) - et al.
Effect of continuous positive airway pressure vs placebo continuous positive airway pressure on sleep quality in obstructive sleep apnea
Chest
(1999) - et al.
Continuous positive airway pressure requirement during the first month of treatment in patients with severe obstructive sleep apnea
Chest
(1998) - et al.
Quality of life in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure; a prospective study
Chest
(1999) - et al.
Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome
Lancet
(1994)
Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomized prospective parallel trial
Lancet
Effect of continuous positive airway pressure treatment on daytime function in sleep apnoea/hypopnoea syndrome
Lancet
Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure
Chest
Adverse effects of nasal continuous positive airway pressure therapy in sleep apnoea syndrome
J Laryngol Otol
Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea
Am Rev Respir Dis
Cited by (107)
Best Predictors of Continuous Positive Airway Pressure Adherence
2022, Sleep Medicine ClinicsSleep Apnea Syndrome (SAS) Clinical Practice Guidelines 2020
2022, Respiratory InvestigationPositive airway pressure I: Equipment
2020, Obesity Hypoventilation Syndrome: From Physiologic Principles to Clinical PracticeNasal pillow vs. standard nasal mask for treatment of OSA: a systematic review and meta-analysis
2023, Sleep and Breathing
This study was supported by a grant from Mallinckrodt Corporation. No other payments, excluding the cost of conducting the study, were made to the authors. The authors have no proprietary, financial, or equity interest in either the sponsor or the product. The authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and the accuracy of the data analysis. Mallinckrodt Corporation assisted in the design of the study, but had no involvement in the collection, analysis, and interpretation of the data; in the writing of the report; and in the decision to submit for publication.